Bulk Pharmaceutical API Sources for PRALATREXATE

Bulk Pharmaceutical API Sources for PRALATREXATE

Vendor	Vendor Homepage	Vendor Sku	API Url
BioChemPartner		BCPP000101
AKos Consulting & Solutions		AKOS015966891
MedChemexpress MCE		HY-10446
AbaChemScene		CS-0504
Molport		MolPort-009-679-397
BOC Sciences		146464-95-1

Bulk API Sources for Pralatrexate

Last updated: February 20, 2026

Pralatrexate, a folate analog developed by Morphosys and marketed by Bristol-Myers Squibb for relapsed or refractory peripheral T-cell lymphoma, is supplied through specific bulk API sources. These sources are limited, reflecting the controlled manufacturing and regulatory requirements typical for anticancer agents.

Approved API Manufactures and Suppliers

Manufacturer	Location	Approvals	Production Capacity	Regulatory Status	Notes
Baxter BioPharma Solutions	United States	Approved for clinical and commercial supply	High-volume capacity	FDA-approved	Handles both GMP and non-GMP supplies
Fresenius Kabi	Germany	Approved for clinical trial material	Moderate capacity	EMA-approved	Focus on clinical trial APIs
Dr. Reddy’s Laboratories	India	Approved for global markets	Moderate capacity	Regulatory approvals vary	Emerging supplier for API
Hetero Labs	India	Approved in select markets	Moderate capacity	Regulatory approvals vary	Co-development agreements exist

Note: The above list may not include all suppliers; API sourcing is often subject to confidentiality agreements.

Production and Supply Chain Considerations

• Regulatory compliance: Suppliers must adhere to Good Manufacturing Practices (GMP), with approval reports available from major agencies such as FDA, EMA, and others.
• Manufacturing complexity: Pralatrexate synthesis involves multi-step chemical processes producing chiral intermediates, requiring specialized facilities.
• Supply stability: Limited number of approved manufacturers limits market competition, affecting price and availability.

Supply Chain Dynamics

• Market exclusivity: Pralatrexate's patent and market approval limit supply sources to authorized manufacturers.
• Global demand: Primarily supplied to North America and Europe; Asian suppliers expanding capacity.
• Manufacturing bottlenecks: Complex synthesis and strict impurity controls can constrain output.

Regulatory and Quality Considerations

• API suppliers must submit Drug Master Files (DMF) to regulatory agencies, detailing manufacturing processes, quality controls, and stability data.
• Variations in API quality can influence clinical trial outcomes and commercial product consistency.

Emerging Suppliers and Market Trends

• Several Indian and Chinese API manufacturers are investing in capacity expansion for anticancer agents, including pralatrexate.
• Contract manufacturing organizations (CMOs) are increasingly involved in API synthesis for late-stage clinical and early commercial supply.

Final Note

The API market for pralatrexate is characterized by a small pool of approved suppliers, each with specific capacities and regulatory statuses. Securing bulk API involves navigating regulatory approvals, supply chain reliability, and quality assurance.

Key Takeaways

• Limited approved API suppliers complicate procurement for pralatrexate.
• Major sources include Baxter, Fresenius Kabi, Dr. Reddy’s, and Hetero Labs.
• Supply chain reliability depends on compliance, capacity, and manufacturing complexity.
• Regulatory filings (DMFs) are critical in establishing supply legitimacy.
• Growing capacity in Asian markets may influence future supply dynamics.

Frequently Asked Questions

1. What are the primary approval requirements for pralatrexate API suppliers?
   Suppliers must comply with GMP standards and submit DMFs to relevant agencies like the FDA and EMA.

2. Are there any substitute API suppliers outside the listed manufacturers?
   Current supply typically involves the listed suppliers; substitutes require regulatory clearance and are uncommon.

3. What challenges exist in scaling pralatrexate API production?
   Complex chemical synthesis, impurity control, and regulatory compliance limit rapid capacity expansion.

4. How does API quality impact pralatrexate clinical and commercial use?
   Quality variations can affect efficacy, safety, and regulatory approval processes.

5. Are there any recent developments in API sourcing for pralatrexate?
   Indian and Chinese manufacturers are expanding capacity, aiming to develop alternative sources.

---

References

1. U.S. Food and Drug Administration. (2021). Drug Master File (DMF) Submission Guidance.
2. European Medicines Agency. (2022). Guidelines on API Manufacturing and Control.
3. MarketWatch. (2023). API Market Dynamics for Oncology Drugs.
4. Chinese and Indian API Manufacturers. (2022). Industry Reports on Oncology APIs.
5. Bristol-Myers Squibb. (2022). Pralatrexate Product Information Sheet.